期刊
EMERGING INFECTIOUS DISEASES
卷 21, 期 6, 页码 992-1001出版社
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid2106.141873
关键词
-
资金
- National Institutes of Health Fogarty International Center [D43TW007124]
- National Institute of Allergy and Infectious Diseases [K23AI103044]
- Atlanta Clinical and Translational Science Institute [UL1TR000454]
- Emory University Global Health Institute
Rates and risk factors for acquired drug resistance and association with outcomes among patients with multidrug-resistant tuberculosis (MDR TB) are not well defined. In an MDR TB cohort from the country of Georgia, drug susceptibility testing for second-line drugs (SLDs) was performed at baseline and every third month. Acquired resistance was defined as any SLD whose status changed from susceptible at baseline to resistant at follow-up. Among 141 patients, acquired resistance in Mycobacterium tuberculosis was observed in 19 (14%); prevalence was 9.1% for ofloxacin and 9.8% for capreomycin or kanamycin. Baseline cavitary disease and resistance to >= 6 drugs were associated with acquired resistance. Patients with M. tuberculosis that had acquired resistance were at significantly increased risk for poor treatment outcome compared with patients without these isolates (89% vs. 36%; p<0.01). Acquired resistance occurs commonly among patients with MDR TB and impedes successful treatment outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据